Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 78 points (-0.5%) at 14,583 as of Wednesday, April 3, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 720 issues advancing vs. 2,193 declining with 115 unchanged. The Health Care sector currently sits down 1.0% versus the S&P 500, which is down 0.7%. On the negative front, top decliners within the sector include Tenet Healthcare ( THC), down 5.9%, Pharmacyclics Incorporated ( PCYC), down 5.5%, HCA Holdings ( HCA), down 4.7%, Sanofi ( SNY), down 0.8% and Baxter International ( BAX), down 0.7%. TheStreet Ratings group would like to highlight 5 stocks pushing the sector lower today: 5. Biogen Idec ( BIIB) is one of the companies pushing the Health Care sector lower today. As of noon trading, Biogen Idec is down $2.88 (-1.4%) to $195.31 on heavy volume Thus far, 1.2 million shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.5 million shares. The stock has ranged in price between $195.14-$199.05 after having opened the day at $198.38 as compared to the previous trading day's close of $198.19. Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $45.6 billion and is part of the drugs industry. The company has a P/E ratio of 33.5, above the S&P 500 P/E ratio of 17.7. Shares are up 35.4% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 11 rate it a hold. TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, revenue growth, largely solid financial position with reasonable debt levels by most measures, good cash flow from operations and growth in earnings per share. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now. Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100%. See his top picks for 14-days FREE.